Norovirus GII.4 (GII.4)

Norovirus GII.4 (Genogroup II, Genotype 4) is the predominant viral strain cluster responsible for the majority of acute gastroenteritis outbreaks globally, often referred to as 'winter vomiting disease' [7, 16]. It is a non-enveloped, positive-sense single-stranded RNA virus within the Caliciviridae family that undergoes rapid antigenic evolution, leading to the periodic emergence of new pandemic variants such as GII.4 Sydney [6, 14, 16]. The virus infects host intestinal cells by binding to histo-blood group antigens (HBGAs), a process dictated by the host's secretor status as determined by the FUT2 gene [7, 8]. The viral life cycle depends on essential non-structural proteins, including a 3C-like protease (NS6) for polyprotein cleavage and an RNA-dependent RNA polymerase (NS7) for genome replication, both of which are primary targets for small-molecule drug discovery [1, 10, 11]. Currently, therapeutic development is heavily focused on virus-like particle (VLP) vaccines, such as TAK-214 (HIL-214), which aim to induce antibodies that block viral attachment to host cell receptors [13, 15]. Challenges in targeting GII.4 include its significant genetic diversity and the ability of new variants to escape existing herd immunity, necessitating the development of broadly protective or multivalent interventions [12, 17, 18].

Other names

Human Norovirus GII.4Norovirus Genogroup II Genotype 4GII.4 SydneyGII.4 New OrleansGII.4 Den HaagGII.4 YersekeGII.4 Farmington HillsWinter vomiting disease virus

Vaccine-mediated immune response elicitation, viral 3C-like protease inhibition, RNA-dependent RNA polymerase inhibition, and blocking of histo-blood group antigen (HBGA) receptor binding.